美国监管机构8月30日批准一种基于改造患者自身免疫细胞的疗法治疗白血病,这是第一种在美国获得批准的基因疗法。专家认为,这开辟了癌症治疗的新篇章。
US regulators on Wednesday approved the first gene therapy against cancer - a treatment that uses a patient's own immune cells to fight leukemia - opening a new era in the fight against one of the world's top killers.
美国监管机构于8月30日批准了首个对抗癌症的基因治疗手段——使用患者的免疫细胞对抗白血病。白血病是世界上致死率最高的疾病之一,该治疗手段开启了对抗白血病的新纪元。
The treatment is made by Novartis and is called Kymriah.
该疗法由诺华公司研发,并被命名为Kymriah。
This type of anti-cancer immunotherapy, known as a CAR-T cell therapy, was known by CTL019 until now.
这种对抗癌症的免疫疗法也被称作CAR-T细胞疗法,并因CTL019疗法(一种CAR-T细胞疗法)被人们熟知。
"This marks the first-ever CAR-T cell therapy to be approved anywhere in the world," Novartis CEO Joseph Jimenez told reporters on a conference call.
诺华CEO江慕忠在一次电话会议上对记者说:“这是全球首次允许使用CAR-T细胞疗法。”
"It uses a new approach that is wholly personalized by using a patient's own T-cells."
“这种新疗法使用患者自己的T细胞,是完全个性化的。”
【首个白血病治疗基因疗法在美获批】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15